TONIX PHARMACEUTICALS HOLDIN (TNXP) Fundamental Analysis & Valuation

NASDAQ:TNXP • US8902608392

Current stock price

13.9 USD
+0.22 (+1.61%)
At close:
13.65 USD
-0.25 (-1.8%)
After Hours:

This TNXP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TNXP Profitability Analysis

1.1 Basic Checks

  • In the past year TNXP has reported negative net income.
  • In the past year TNXP has reported a negative cash flow from operations.
  • In the past 5 years TNXP always reported negative net income.
  • In the past 5 years TNXP always reported negative operating cash flow.
TNXP Yearly Net Income VS EBIT VS OCF VS FCFTNXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M

1.2 Ratios

  • With a Return On Assets value of -44.75%, TNXP perfoms like the industry average, outperforming 52.22% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -50.59%, TNXP is in the better half of the industry, outperforming 62.86% of the companies in the same industry.
Industry RankSector Rank
ROA -44.75%
ROE -50.59%
ROIC N/A
ROA(3y)-66.7%
ROA(5y)-58.04%
ROE(3y)-84.77%
ROE(5y)-70.59%
ROIC(3y)N/A
ROIC(5y)N/A
TNXP Yearly ROA, ROE, ROICTNXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • The Gross Margin of TNXP (49.34%) is better than 74.47% of its industry peers.
  • The Profit Margin and Operating Margin are not available for TNXP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNXP Yearly Profit, Operating, Gross MarginsTNXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. TNXP Health Analysis

2.1 Basic Checks

  • TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TNXP has been increased compared to 1 year ago.
  • The number of shares outstanding for TNXP has been increased compared to 5 years ago.
  • There is no outstanding debt for TNXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TNXP Yearly Shares OutstandingTNXP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
TNXP Yearly Total Debt VS Total AssetsTNXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • TNXP has an Altman-Z score of -1.42. This is a bad value and indicates that TNXP is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -1.42, TNXP perfoms like the industry average, outperforming 51.45% of the companies in the same industry.
  • There is no outstanding debt for TNXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.42
ROIC/WACCN/A
WACC9.18%
TNXP Yearly LT Debt VS Equity VS FCFTNXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • TNXP has a Current Ratio of 7.42. This indicates that TNXP is financially healthy and has no problem in meeting its short term obligations.
  • TNXP has a better Current ratio (7.42) than 69.44% of its industry peers.
  • TNXP has a Quick Ratio of 7.23. This indicates that TNXP is financially healthy and has no problem in meeting its short term obligations.
  • TNXP's Quick ratio of 7.23 is fine compared to the rest of the industry. TNXP outperforms 68.47% of its industry peers.
Industry RankSector Rank
Current Ratio 7.42
Quick Ratio 7.23
TNXP Yearly Current Assets VS Current LiabilitesTNXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. TNXP Growth Analysis

3.1 Past

  • TNXP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.44%, which is quite impressive.
  • The Revenue has grown by 29.85% in the past year. This is a very strong growth!
EPS 1Y (TTM)99.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.26%
Revenue 1Y (TTM)29.85%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%108.75%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.76% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 126.50% on average over the next years. This is a very strong growth
EPS Next Y44.27%
EPS Next 2Y33.38%
EPS Next 3Y22.76%
EPS Next 5YN/A
Revenue Next Year708.37%
Revenue Next 2Y231.62%
Revenue Next 3Y126.5%
Revenue Next 5YN/A

3.3 Evolution

TNXP Yearly Revenue VS EstimatesTNXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
TNXP Yearly EPS VS EstimatesTNXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -500M -1B -1.5B

More info and screens

Find the best growth stocksShow best growing peers

1

4. TNXP Valuation Analysis

4.1 Price/Earnings Ratio

  • TNXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNXP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNXP Price Earnings VS Forward Price EarningsTNXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNXP Per share dataTNXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as TNXP's earnings are expected to grow with 22.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.38%
EPS Next 3Y22.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TNXP Dividend Analysis

5.1 Amount

  • No dividends for TNXP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TNXP Fundamentals: All Metrics, Ratios and Statistics

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (4/2/2026, 8:00:01 PM)

After market: 13.65 -0.25 (-1.8%)

13.9

+0.22 (+1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-11
Inst Owners29.57%
Inst Owner Change49.28%
Ins Owners0.07%
Ins Owner Change0%
Market Cap186.40M
Revenue(TTM)13.11M
Net Income(TTM)-124.02M
Analysts82.5
Price Target67.66 (386.76%)
Short Float %18.46%
Short Ratio6.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.25%
Min EPS beat(2)-22.32%
Max EPS beat(2)1.82%
EPS beat(4)2
Avg EPS beat(4)-6.1%
Min EPS beat(4)-22.32%
Max EPS beat(4)13.8%
EPS beat(8)5
Avg EPS beat(8)-32.16%
EPS beat(12)7
Avg EPS beat(12)-19.12%
EPS beat(16)10
Avg EPS beat(16)-9.21%
Revenue beat(2)2
Avg Revenue beat(2)43.66%
Min Revenue beat(2)4.05%
Max Revenue beat(2)83.27%
Revenue beat(4)2
Avg Revenue beat(4)15.3%
Min Revenue beat(4)-19.5%
Max Revenue beat(4)83.27%
Revenue beat(8)2
Avg Revenue beat(8)-6.36%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.96%
EPS NY rev (1m)0%
EPS NY rev (3m)5.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-40.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.22
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-14.27
EYN/A
EPS(NY)-7.95
Fwd EYN/A
FCF(TTM)-7.7
FCFYN/A
OCF(TTM)-7.45
OCFYN/A
SpS0.98
BVpS18.28
TBVpS18.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.75%
ROE -50.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.34%
FCFM N/A
ROA(3y)-66.7%
ROA(5y)-58.04%
ROE(3y)-84.77%
ROE(5y)-70.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 175.01%
Cap/Sales 25.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.42
Quick Ratio 7.23
Altman-Z -1.42
F-Score5
WACC9.18%
ROIC/WACCN/A
Cap/Depr(3y)120.84%
Cap/Depr(5y)14966.9%
Cap/Sales(3y)42.84%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.26%
EPS Next Y44.27%
EPS Next 2Y33.38%
EPS Next 3Y22.76%
EPS Next 5YN/A
Revenue 1Y (TTM)29.85%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%108.75%
Revenue Next Year708.37%
Revenue Next 2Y231.62%
Revenue Next 3Y126.5%
Revenue Next 5YN/A
EBIT growth 1Y-61.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.88%
OCF growth 3YN/A
OCF growth 5YN/A

TONIX PHARMACEUTICALS HOLDIN / TNXP Fundamental Analysis FAQ

What is the fundamental rating for TNXP stock?

ChartMill assigns a fundamental rating of 4 / 10 to TNXP.


What is the valuation status of TONIX PHARMACEUTICALS HOLDIN (TNXP) stock?

ChartMill assigns a valuation rating of 1 / 10 to TONIX PHARMACEUTICALS HOLDIN (TNXP). This can be considered as Overvalued.


Can you provide the profitability details for TONIX PHARMACEUTICALS HOLDIN?

TONIX PHARMACEUTICALS HOLDIN (TNXP) has a profitability rating of 1 / 10.


What is the financial health of TONIX PHARMACEUTICALS HOLDIN (TNXP) stock?

The financial health rating of TONIX PHARMACEUTICALS HOLDIN (TNXP) is 7 / 10.